Phase 1 N=11 Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=54 A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-1 on Plasma Ferritin Levels — 592.3; 538.8; 313.7; 308.2 Percent change from baseline
Phase 1 N=18 A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-3 on Plasma Ferritin Levels — 2.49; 4.42; 4.90 Ratio (24 h post-infusion over baseline)
Phase 1 N=42 A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-9 on Plasma Ferritin Levels — -9.83; 7.66; 39.37 Percent change from baseline
Phase 1 N=16 PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
Renal Impairment · Renal Insufficiency · Kidney Disease
Primary: AUC — 102.0; 168.9; 107.4; 188.5 h*ng/mL
Phase 1 N=64 A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
Kidney Failure, Chronic
Primary: Number of Participants With One or More Serious Adverse Event (s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0…
Phase 1 N=7 A Study of LY3113593 in Participants With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1 Participants
Phase 4 N=16 Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers
Severe Renal Impairment
Primary: Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL)) — 175; 145 nanogram hour per milliliter (ng•h/mL)
Phase 2 N=210 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Anemia · Chronic Kidney Disease
Primary: Percentage of Participants Achieving a Successful Hemoglobin Response — 54.9; 10.3 Percentage of participants — p==0.0001
Phase 2 N=91 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Anemia · Kidney Disease
Primary: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) — 9.46; 9.93; 9.86; 9.67 Grams per deciliter (g/dL) — p=<0.0001
Phase 2 N=261 A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.210; -0.190; -0.217; 0.018…
Phase 1 N=14 A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
End-Stage Renal Disease · End-Stage Kidney Disease · Kidney Failure, Chronic
Primary: Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0; 0 Participants
Phase 2 N=10 Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Anemia · Kidney Disease
Primary: Mean Change From Baseline in Hemoglobin (Hgb) on Day 29 — 9.91; 0.63 Grams per decilitre (g/dL) — p=0.0020
Phase 1 N=32 PF-04634817 Renal Impairment Study
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Phase 2 N=714 A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
Kidney Disease, Chronic
Primary: Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients…
N/A N=34 Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
Chronic Kidney Disease · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D — 18.6; 17.3; 19.5; 49.4 ng/mL
Phase 1 N=23 Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Renal Impairment
Primary: Dose-Normalized Maximum Concentration of Plerixafor (Cmax) — 0.0452; 0.0388; 0.0490; 0.0475 ng/mL/ug
Phase 1 N=36 PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
Hepatic Impairment · Liver Diseases · Digestive System Diseases
Primary: AUC — 113.5; 114.6; 423.7; 1042 h*ng/mL
Phase 2 N=12 Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function
Pharmacokinetics · Renal Impaired · Healthy Volunteer
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 0.5; 0.5; 0.5; 0.5 hour
Phase 3 N=22 Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
Diabetes Mellitus · Chronic Kidney Disease · Diabetic Kidney Disease
Primary: Change in Urine Albumin Excretion — -21; -5 percent difference
Phase 3 N=202 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Hyperphosphatemia
Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001
Phase 1 N=14 A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
End Stage Renal Disease · Renal Impairment
Primary: Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf) — 17100; 21100; 18500 ng•hr/mL
Phase 1 N=40 Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)
Healthy Volunteers · Renal Impairment
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Last Measurable Concentration (AUC0-last) of MK-6183 — 87.6; 114.8; 97.5; 228.0 ug*hr/mL
Phase 2 N=94 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Anemia · End Stage Renal Disease
Primary: Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average — 10.43; 10.55; 10.52; 0.00 Grams per deciliter (g/dL)
Phase 2 N=22 Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
Chronic Kidney Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 6; 2 Participants
Phase 3 N=632 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL
Phase 1 N=42 A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Phase 2 N=349 Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
Kidney Failure, Chronic
Primary: Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo) — -0.0; -0.6; -1.2; -1.8 mg/dL — p=0.0249
Phase 2 N=135 Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Acidosis
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE — 14; 13; 9; 17 Participants
Phase 1 N=42 Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
Renal Impairment
Primary: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf) — 104; 141; 83.5; 244 µM*hr